Waldron Private Wealth’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-550
Closed -$54.3K 497
2024
Q3
$54.3K Buy
+550
New +$54K ﹤0.01% 437
2022
Q2
Sell
-5,096
Closed -$458K 409
2022
Q1
$458K Buy
+5,096
New +$471K 0.02% 262

Other funds holding XBI

Waldron Private Wealth's XBI Position: Q4 2024 in Review

Waldron Private Wealth sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 550 shares — an estimated $54.3K sold.

Waldron Private Wealth first reported a position in XBI in Q1 2022 and held it in 2 quarters. The position peaked at $458K in Q1 2022. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

  • Waldron Private Wealth reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
  • Waldron Private Wealth sold 550 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $54.3K.
  • Waldron Private Wealth first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 2 quarters.
  • Waldron Private Wealth's State Street SPDR S&P Biotech ETF position peaked at $458K in Q1 2022.
  • 738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on Waldron Private Wealth's 13F filing for Q4 2024, filed 24 Jan 2025.